Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Community-acquired pneumonia,Acute bacterial sinusitis,Acute bacterial exacerbation of chronic bronchitis,Skin and skin structure infections (uncomplicated and complicated),Complicated intra-abdominal infections,Pelvic inflammatory disease,Urinary tract infections (complicated and uncomplicated),Prophylaxis of anthrax exposure,Plague,Empiric therapy in febrile neutropenia (off-label)
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
400 mg intravenously once daily.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
12-15 hours (terminal elimination half-life; allows once-daily dosing; may be prolonged in renal impairment).
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Moxifloxacin undergoes sulfate conjugation (phase II metabolism) via sulfotransferases; it is not metabolized by cytochrome P450 enzymes. Approximately 20% is excreted unchanged in urine, and 25% as a glucuronide conjugate.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal (~20% unchanged, plus ~35% as glucuronide and sulfate conjugates), biliary/fecal (~25% unchanged and conjugates, total ~50% via feces).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
~50% bound, primarily to serum albumin.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
2.5–3.5 L/kg (indicates extensive tissue penetration, including lung and sinuses).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Oral: ~90% (bioequivalent to IV).
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No dose adjustment required for GFR ≥30 m L/min; insufficient data for GFR <30 m L/min, use with caution.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No dose adjustment for Child-Pugh A or B; not recommended for Child-Pugh C due to lack of data.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Not recommended for patients <18 years due to risk of musculoskeletal adverse effects.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
No specific dose adjustment; monitor for QT prolongation and tendon effects.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Fluoroquinolones, including moxifloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients over 60 years of age, in those taking corticosteroids, and in kidney, heart, or lung transplant recipients. Fluoroquinolones may exacerbate muscle weakness in patients with myasthenia gravis. Avoid use in patients with known myasthenia gravis.
None.
Tendon injury (tendinitis, tendon rupture),Worsening of myasthenia gravis,Peripheral neuropathy, irreversible,Central nervous system effects (seizures, dizziness, confusion),QT prolongation (avoid in patients with known QTc prolongation, electrolyte abnormalities, or concomitant QT-prolonging drugs),Hypersensitivity/anaphylactic reactions,Clostridioides difficile-associated diarrhea,Photosensitivity/phototoxicity,Blood glucose disturbances (especially in diabetic patients on oral hypoglycemics or insulin),Avoid in patients with known aortic aneurysm or at risk for aortic aneurysm
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Known hypersensitivity to moxifloxacin or any fluoroquinolone,Pregnancy (animal data showing fetal harm; avoid unless benefit outweighs risk),Lactation (not recommended; may cause articular damage in nursing infants),Patients under 18 years of age (except for specific approved indications like anthrax),History of tendon disorders related to fluoroquinolone use,Uncorrected hypokalemia or hypomagnesemia (risk of QTc prolongation),Concomitant use with Class IA or Class III antiarrhythmics (QT prolongation risk)
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid concurrent intake of dairy products (milk, yogurt, cheese), antacids containing calcium, magnesium, or aluminum, and supplements with calcium, iron, or zinc. Separate dosing by at least 2 hours before or 6 hours after these products. Caffeine intake should be limited as moxifloxacin may increase its effects (nervousness, insomnia). No other significant food interactions.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Moxifloxacin is contraindicated in pregnant women due to risk of fetal harm. Animal studies show arthropathy and cartilage damage in immature animals. Human data limited; avoid in all trimesters.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Moxifloxacin is excreted in human milk; M/P ratio unknown. Potential for infant joint damage. Avoid breastfeeding or discontinue drug.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No dose adjustment established. Pregnancy is a contraindication; therefore, use only if no alternative and benefit outweighs risk. No pharmacokinetic studies in pregnancy.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Moxifloxacin is a fourth-generation fluoroquinolone with enhanced activity against Gram-positive bacteria and anaerobes. It achieves high tissue penetration, including into the CSF. Avoid in patients with known QT prolongation or uncorrected hypokalemia due to risk of torsades de pointes. Use with caution in elderly patients and those with renal impairment; no dose adjustment needed for renal impairment but adjust for hepatic impairment (Child-Pugh C). Monitor for signs of tendinitis or tendon rupture, especially in patients over 60, those on corticosteroids, or with kidney, heart, or lung transplants. Administer intravenous infusion over 60 minutes to reduce risk of infusion-related reactions.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Take this medication exactly as prescribed; do not skip doses or stop early even if you feel better.,Contact your doctor immediately if you experience tendon pain, swelling, or rupture (especially in the Achilles tendon), or if you have muscle weakness, joint pain, or difficulty moving.,Avoid excessive sunlight or UV light exposure; use sunscreen and protective clothing as this drug can cause photosensitivity.,This drug may cause dizziness or lightheadedness; do not drive or operate machinery until you know how it affects you.,Drink plenty of fluids to stay hydrated, unless instructed otherwise by your doctor.,Inform your doctor if you have a history of seizures, QT prolongation, heart rhythm problems, or if you are taking antiarrhythmics or other drugs that affect heart rhythm.,Do not take with dairy products, antacids, or supplements containing calcium, magnesium, aluminum, or iron; these can reduce drug absorption. Take moxifloxacin at least 2 hours before or 6 hours after these products.,Report any signs of allergic reaction: rash, hives, difficulty breathing, swelling of face, lips, or throat.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Moxifloxacin, a fluoroquinolone antibiotic, and mefloquine, an antimalarial agent, both prolong the QT interval by inhibiting cardiac potassium channels (specifically hERG channels). When coadministered, there is an additive effect on QTc prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias. This interaction is particularly dangerous in patients with preexisting cardiac conditions, electrolyte imbalances, or bradycardia."
"Moxifloxacin, a fluoroquinolone antibiotic, can decrease the therapeutic efficacy of picosulfuric acid, a stimulant laxative used for bowel cleansing. This interaction likely occurs because moxifloxacin exhibits weak antagonistic activity at the 5-HT4 receptors in the gastrointestinal tract, partially counteracting the prokinetic and secretory effects mediated by picosulfuric acid. Consequently, patients may experience reduced bowel cleansing efficacy, potentially leading to inadequate colonic preparation for colonoscopy and increased risk of missed lesions."
"Dronedarone prolongs the QT interval by blocking multiple cardiac ion channels (primarily IKr). Moxifloxacin also prolongs the QT interval by blocking IKr. Coadministration leads to additive QTc prolongation, increasing the risk of torsades de pointes and ventricular arrhythmias. This risk is particularly elevated in patients with pre-existing electrolyte imbalances, bradycardia, or baseline QT prolongation."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is a Electrolyte that works by Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is: 400 mg intravenously once daily.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is classified as Category A/B. Moxifloxacin is contraindicated in pregnant women due to risk of fetal harm. Animal studies show arthropathy and cartilage damage in immature animals. Human data limited; avoid in . ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.